Fautrel et al. found a relapse rate of 77% after 18 months in RA patients tapering ADA and/or ETN every 3 months followed by discontinuation, compared to 47% in RA patient continuing ADA and/or ETN in a standard dose [52]. This evidence concerns the gene ADA and rheumatoid arthritis.